Acquired hemophilia
Acquired hemophilia (AH) refers to a bleeding disease caused by the production of specific autoantibodies that inhibit factor VIII (FVIII) in the body.
-
Site of disease:
Blood vessels -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
Difficulty swallowing intracranial hemorrhage venous thrombosis black stool difficulty swallowing -
Concurrent disease:
Related Drugs
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.
Recombinant Human Coagulation Factor VIIa for Injection
Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.